Brief: Adverum Receives Priority Medicines Designation By EMA For ADVM-022 In Wet AMD
24/06/2022 13:35
June 24 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES GRANTED PRIORITY MEDICINES (PRIME)
DESIGNATION BY EUROPEAN MEDICINES AGENCY FOR ADVM-022 IN WET AMD
* ADVERUM BIOTECHNOLOGIES INC - ANTICIPATES DOSING FIRST
PATIENT
IN Q3 OF 2022
Source text for Eikon: ID:nGNX3dLb6P
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)